

June 29, 2020

To, BSE Limited The Corporate Relationship Dept. P.J. Towers, Dalal Street, Mumbai – 400 001

BSE Company Code: 500214

Dear Sir/ Madam,

Sub: Submission of Analyst / Investor Presentation

Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed presentation being made to Analyst / Institutional Investor to discuss the Financial performance of the Company for the year ended March 31, 2020.

The aforesaid information is also disclosed on website of the company i.e. www.ionindia.com

Kindly take the information on record.

Thanking You,

Yours faithfully, For Ion Exchange (India) Limited

MILLIND DATTATRAY DATTATRAY A PURANIK A PURANIK

Milind Puranik Company Secretary

ION EXCHANGE (INDIA) LTD. | CIN: L74999MH1964PLC014258

Regd. Office: Ion House, Dr. E. Moses Road, Mahalaxmi, Mumbai - 400 011, India. Board: +91 22 6231 2000 | Fax: +91 22 2493 8737 | E-mail: ieil@ionexchange.co.in | Web: www.ionindia.com



Executive Summary

FY20: Operating Income* INR 14,798 Mn

> FY20: Operating EBITDA* INR 1,346 Mn

FY20: PAT* INR 940 Mn

*Consolidated

OVERVIEW

- Ion Exchange (India) Ltd (Ion Exchange), formed in 1964, is a pioneer in water, waste water treatment & environment solutions and caters to various industries, homes & communities.
- Headquartered in Mumbai, the company has six manufacturing & assembly facilities across India, and one each in Bangladesh and UAE. It also has presence across other key geographies.
- Installation: 1 lakh globally; 500+ in core sectors.

BUSINESS & REVENUE (%) MIX -CONSOLIDATED

- Engineering (61%) Provides comprehensive and integrated services and solutions in water & waste water treatment including Sea Water desalination, Recycle and Zero liquid discharge plants to diverse industries.
- Chemicals (31%) Provides a comprehensive range of resins, speciality chemicals and customized chemical treatment programmes for water, non-water and specialty applications.
- Consumer Products (8%) Caters to individuals, hotels, spas, educational institutions, hospitals, laboratories, railway and defence establishments providing safe drinking water and a clean environment.


MARQUEE CLIENTS


- Industrial NTPC, NPC, Reliance, IOCL, JSW, CPCL, L&T, Essar group, IRCTC, BHEL, Tata Group.
- Institutional Leela, Military Engineering Services, Taj Hotels, Holiday Inn, Hyatt Regency, Oberoi Hotels, Apollo Hospitals, Escorts Heart Institute, DLF, Puravankar.
- International Cargill, Technip France, Unilever Group, Jurong, Thyssenkrupp (Uhde), Jacobs, Kawasaki, Mitsubishi, PDO Oman, Emirates Steel, IKPP Indonesia.

Company Overview

- Ion Exchange was originally formed as a subsidiary of Permutit, UK in 1964. It became a wholly owned Indian company in 1985. The company is currently in its 56th Year of operations.
- The company has expanded its footprints globally and possesses a diversified product range. It offers one stop water and non-water treatment solutions catering to diverse segments like infrastructure, industry, institutions, municipal, homes and communities, urban and rural.
- The company offers a wide range of solutions across the water cycle from pretreatment to process water treatment, waste water treatment, recycle, zero liquid discharge, sewage treatment, packaged drinking water, sea water desalination etc.
- The company is also engaged in manufacturing ion exchange resins, speciality chemicals for water and waste water treatment as well as non-water applications.
- It has two facilities for in-house R&D and two applications and testing centers.
- The company has over 50 patents to their credit and 100+ products commercialized.
- The company has a global presence apart from presence in major cities in India with sales & service centers and dealer network of more than 100.
- The company exports to Africa, Japan, Middle East, Russia, South East Asia, Europe, UK, USA, Canada and neighbouring countries.

REVENUE BREAK UP FY20*





FY20 / Q4-FY20 FINANCIAL HIGHLIGHTS

- **Q4-FY20** Performance (Standalone):
 - Operating Income: INR 3,279 Mn
 - Operating EBITDA: INR 327 Mn
 - Operating EBITDA Margins: 9.97%
 - Net Profit: INR 289 Mn
 - PAT Margins: 8.81%
 - Diluted EPS: INR 23.49 per share
- **FY20** Performance (Standalone):
 - Operating Income: INR 14,072 Mn
 - Operating EBITDA: INR 1,210 Mn
 - Operating EBITDA Margins: 8.60%
 - Net Profit: INR 991 Mn
 - PAT Margins: 7.04%
 - Diluted EPS: INR 81.85 per share

- **Q4-FY20** Performance (Consolidated):
 - Operating Income: INR 3,511 Mn
 - Operating EBITDA: INR 393 Mn
 - Operating EBITDA Margins: 11.19%
 - Net Profit: INR 287 Mn
 - PAT Margins: 8.17%
 - Diluted EPS: INR 24.22 per share
- **FY20** Performance (Consolidated):
 - Operating Income: INR 14,798 Mn
 - Operating EBITDA: INR 1,346 Mn
 - Operating EBITDA Margins: 9.10%
 - Net Profit: INR 940 Mn
 - PAT Margins: 6.35%
 - Diluted EPS: INR 80.55 per share

FY20 / Q4-FY20 OPERATIONAL HIGHLIGHTS

Business Operations

- > Operations of the Company were affected in Q4-FY20 due to COVID 19 pandemic and the resultant lockdowns in several geographies including India.
- > This resulted in deferral of despatches in all the three segments thereby impacting the sales and margins.
- > Currently with the phase wise lifting of the lockdown, all our manufacturing operations and offices at most of the locations are functional.
- > We have invoked FORCE MAJEURE clause for all our major projects where the Company foresees contractual delays due to the lockdown.

Engineering

- Revenue recognition for the Sri Lanka project in the quarter was affected due to the COVID 19 lockdown impact. Post receipt of necessary permissions from the Sri Lanka Govt, we have recently resumed our supplies and civil works.
- Whilst the Engineering order book remains healthy, the order intake for the quarter was muted due to the general economy slowdown and the delay in order finalisations caused by the lockdown.

Chemicals

Margins improved due to operational efficiencies resulting from the capacity increases coupled with change in product mix due to seasonality of certain product lines.

Consumer


> Adverse impact of the COVID 19 lockdown significantly affected the volumes thereby resulting in lower recovery of fixed costs.

Q4-FY20 STANDALONE INCOME STATEMENT (IND-AS)

| INCOME STATEMENT (INR MN) | | Q4-FY20 | Q4-FY19 | Y-o-Y | Q3-FY20 | Q-o-Q |
|---|--|---------|---------|-----------|--------------------|----------------|
| Operating Income | | 3,279 | 4,181 | (21.6)% | 3,781 | (13.3)% |
| Expenses | | 2,952 | 3,677 | (19.7)% | 3,413 | (13.5)% |
| Operating EBITDA | | 327 | 504 | (35.1)% | 368 | (11.1)% |
| Operating EBITDA Margins (%) | | 9.97% | 12.05% | (208) Bps | 9.73% | 24 Bps |
| Depreciation | | 61 | 47 | 29.8% | 55 | 10.9% |
| Finance Cost | | 32 | 42 | (23.8)% | 35 | (8.6)% |
| Other Income | | 155 | 48 | NA | 104 | 49.0% |
| РВТ | | 389 | 463 | (16.0)% | 382 | 1.8% |
| Тах | | 100 | 155 | (35.5)% | 104 | (3.8)% |
| Profit After Tax | | 289 | 308 | (6.2)% | 278 | 4.0% |
| PAT Margins (%) | | 8.81% | 7.37% | 144 Bps | 7.35% | 146 Bps |
| Other Comprehensive Income | | (5) | (4) | NA | (2) | NA |
| Total Comprehensive Income | | 284 | 304 | (6.6)% | 276 | 2.9% |
| Diluted EPS (INR) | | 23.49# | 25.68* | (8.5)% | 22.87 [#] | 2.7% |
| *Earnings per equity share includes impact of equity shares held by IEI #Earnings per equity share includes impact of equity shares held by | | | | | | shares held bv |

*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914 #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 23,68,939

SEGMENTAL BREAKUP- QUARTERLY STANDALONE




STANDALONE INCOME STATEMENT (IND-AS)

| INCOME STATEMENT (INR MN) | FY20 | FY19 | Y-o-Y | |
|--|--------------------|--------|---------|--|
| Operating Income | 14,072 | 11,023 | 27.7% | |
| Expenses | 12,862 | 10,110 | 27.2% | |
| Operating EBITDA | 1,210 | 913 | 32.5% | |
| Operating EBITDA Margins (%) | 8.60% | 8.28% | 32 Bps | |
| Depreciation | 221 | 181 | 22.1% | |
| Finance Cost | 132 | 162 | (18.5)% | |
| Other Income | 485 | 441 | 10.0% | |
| РВТ | 1,342 | 1,011 | 32.7% | |
| Tax | 351 | 345 | 1.7% | |
| Profit After Tax | 991 | 666 | 48.8% | |
| PAT Margins (%) | 7.04% | 6.04% | 100 Bps | |
| Other Comprehensive Income | (9) | (5) | NA | |
| Total Comprehensive Income | 982 | 661 | 48.6% | |
| Diluted EPS (INR) | 81.85 [#] | 55.47* | 47.6% | |
| *Earnings per equity share includes impact of equity shares held by IEI #Earnings per equity share includes impact of equity shares held | | | | |

Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914 #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 23,68,939


SEGMENTAL BREAKUP- STANDALONE



STANDALONE BALANCE SHEET (As Per IND-AS)

| PARTICULARS (INR MN) | FY20 | FY19 | PARTICULARS (INR MN) | FY20 | FY19 |
|--|--------|--------|-----------------------------------|--------|--------|
| EQUITIES & LIABILITIES | | | ASSETS | | |
| Equity | | | Non-Current Assets | | |
| (A) Equity Share Capital | 147 | 147 | (A) Property, Plant and Equipment | 1,623 | 1,425 |
| (B) Other Equity | 4,668 | 3,597 | (B) Capital Work-in-progress | 179 | 123 |
| Total Equity | 4,815 | 3,744 | (C) Right-of-Use Assets | 67 | - |
| Non-Current Liabilities | | | (D) Other Intangible Assets | 16 | 14 |
| (A) Financial Liabilities | | | (E) Financial Assets | | |
| (i) Borrowings | 271 | 261 | (i) Investments | 620 | 607 |
| (ii) Lease Liabilities | 17 | - | (ii) Trade Receivables | 29 | 36 |
| (iii) Other financial Liabilities | 81 | 81 | (iii) Loans | 420 | 403 |
| (B) Provisions | 140 | 118 | (F) Other Non-Current Assets | 53 | 63 |
| (C) Deferred Tax Liabilities (Net) | - | 11 | (G) Deferred Tax Assets | 6 | - |
| (D) Liabilities for Non-Current Tax (Net) | 19 | 15 | Total Non – Current Assets | 3,013 | 2,671 |
| Total Non – Current Liabilities | 528 | 486 | Current Assets | | |
| Current Liabilities | | | (A) Inventories | 1,180 | 1,092 |
| (A) Financial Liabilities | | | (B) Financial Assets | | |
| (i) Borrowings | 640 | 434 | (i) Investments | 1 | 4 |
| (ii) Lease Liabilities | 15 | - | (ii) Trade Receivables | 5,137 | 4,276 |
| (iii) Trade Payables | 4,570 | 3,948 | (iii) Cash & Cash Equivalents | 846 | 360 |
| (iv) Other Financial Liabilities | 475 | 380 | (iv) Bank Balances | 2,691 | 2,394 |
| (B) Other Current Liabilities | 3,118 | 2,979 | (v) Loans | 472 | 509 |
| (C) Provisions | 49 | 38 | (vi) Other Financial Assets | 224 | 184 |
| (D) Liabilities for current tax (Net) | 157 | 141 | (C) Other current assets | 803 | 660 |
| Total Current Liabilities | 9,024 | 7,920 | Total Current Assets | 11,354 | 9,479 |
| GRAND TOTAL - EQUITIES & LIABILITES | 14,367 | 12,150 | GRAND TOTAL – ASSETS | 14,367 | 12,150 |
| | | | | | 10 |

FINANCIALS - STANDALONE




Q4-FY20 CONSOLIDATED INCOME STATEMENT (IND-AS)

| INCOME STATEMENT (INR MN) | Q4-FY20 | Q4-FY19 | Ү-о-Ү | Q3-FY20 | Q-o-Q |
|---|--|---------|-----------|--------------------|---------|
| Operating Income | 3,511 | 4,318 | (18.7)% | 3,982 | (11.8)% |
| Expenses | 3,118 | 3,719 | (16.2)% | 3,590 | (13.1)% |
| Operating EBITDA | 393 | 599 | (34.4)% | 392 | 0.3% |
| Operating EBITDA Margins (%) | 11.19% | 13.87% | (268) Bps | 9.84% | 135 Bps |
| Depreciation | 65 | 51 | 27.5% | 59 | 10.2% |
| Finance Cost | 40 | 49 | (18.4)% | 42 | (4.8)% |
| Other Income | 109 | 20 | NA | 76 | 43.4% |
| PBT | 397 | 519 | (23.5)% | 367 | 8.2% |
| Share of Profit of equity accounted Investee | (4) | 2 | NA | 3 | NA |
| Тах | 106 | 160 | (33.8)% | 107 | (0.9)% |
| Profit After Tax | 287 | 361 | (20.5)% | 263 | 9.1% |
| PAT Margins (%) | 8.17% | 8.36% | (19) Bps | 6.60% | 157 Bps |
| Other Comprehensive Income | 13 | (4) | NA | (7) | NA |
| Total Comprehensive Income | 300 | 357 | (16.0)% | 256 | 17.2% |
| Diluted EPS (INR) | 24.22# | 31.17* | (22.3)% | 22.50 [#] | 7.6% |
| *Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. | by IEI #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. | | | | |

No. of Shares- 26,62,914

No. of Shares- 23,68,939

SEGMENTAL BREAKUP-QUARTERLY CONSOLIDATED




CONSOLIDATED INCOME STATEMENT (As per IND-AS)

| INCOME STATEMENT (INR MN) | FY20 | FY19 | Ү-о-Ү |
|--|--------|--------|---------|
| Operating Income | 14,798 | 11,623 | 27.3% |
| Expenses | 13,452 | 10,557 | 27.4% |
| Operating EBITDA | 1,346 | 1,066 | 26.3% |
| Operating EBITDA Margins (%) | 9.10% | 9.17% | (7) Bps |
| Depreciation | 237 | 196 | 20.9% |
| Finance Cost | 160 | 190 | (15.8)% |
| Other Income | 354 | 333 | 6.3% |
| PBT | 1,303 | 1,013 | 28.6% |
| Share of Profit of equity accounted Investee | 4 | 5 | (20.0)% |
| Tax | 367 | 359 | 2.2% |
| Profit After Tax | 940 | 659 | 42.6% |
| PAT Margins (%) | 6.35% | 5.67% | 68 Bps |
| Other Comprehensive Income | 2 | 1 | NA |
| Total Comprehensive Income | 942 | 660 | 42.7% |
| EPS Diluted (INR) | 80.55# | 56.99* | 41.3% |
| | | | |

*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts (No. of Shares-26,62,914) and shares held by Subsidiary companies (No. of Shares- 4,37,874)

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts (No. of Shares-23,68,939) and shares held by Subsidiary companies (No. of Shares- 4,37,874)


SEGMENTAL BREAKUP- CONSOLIDATED




CONSOLIDATED BALANCE SHEET (IND-AS)


| PARTICULARS (INR MN) | FY20 | FY19 | PARTICULARS (INR MN) | FY20 | FY19 |
|---|--------|--------|--|--------|--------|
| EQUITIES & LIABILITIES | | | ASSETS | | |
| Equity | | | Non-Current Assets | | |
| (A) Equity Share Capital | 142 | 142 | (A) Property, Plant and Equipment | 1,697 | 1,507 |
| (B) Other Equity | 3,489 | 2,458 | (B) Capital Work-in-progress | 179 | 123 |
| Equity attributable to owners | 3,631 | 2,600 | (C) Right-of-Use Assets | 77 | - |
| Non Controlling Interest | 20 | 22 | (C) Other Intangible Assets | 16 | 14 |
| Total Equity | 3,651 | 2,622 | (D) Goodwill | 86 | 86 |
| | | | (E) Investment accounted using Equity Method | 37 | 34 |
| Non-Current Liabilities | | | (F) Financial Assets | | |
| (A) Financial Liabilities | | | (i) Investments | 7 | 7 |
| (i) Borrowings | 271 | 261 | (ii) Trade Receivables | 62 | 142 |
| (ii) Lease liabilities | 22 | - | (iii) Loans | 118 | 100 |
| (iii) Other Financial Liabilities | 81 | 81 | (iv) Other Financial Assets | 65 | 70 |
| (B) Provisions | 157 | 133 | (G) Deferred Tax Assets (Net) | 15 | 10 |
| (C) Deferred Tax Liabilities (Net) | 5 | 11 | (H) Other Non-Current Assets | 165 | 167 |
| (D) Other Non-Current Liabilities | 5 | 6 | (I) Non-Current Tax Assets | 5 | 5 |
| (E) Liabilities for non-current tax (Net) | 19 | 16 | Total Non – Current Assets | 2529 | 2,265 |
| Total Non – Current Liabilities | 560 | 508 | Current Assets | | |
| | | | (A) Inventories | 1,345 | 1,298 |
| Current Liabilities | | | (B) Financial Assets | | |
| (A) Financial Liabilities | | | (i) Investments | 1 | 4 |
| (i) Borrowings | 858 | 667 | (ii) Trade Receivables | 5,019 | 4,242 |
| (ii) Lease liabilities | 17 | - | (iii) Cash & Cash Equivalents | 1,015 | 452 |
| (iii) Trade Payables | 4,800 | 4,151 | (iv) Bank Balances | 2,716 | 2,452 |
| (iv) Other Financial Liabilities | 518 | 428 | (v) Loans | 173 | 91 |
| (B) Other Current Liabilities | 3,190 | 3,078 | (vi) Other Financial Assets | 237 | 197 |
| (C) Provisions | 57 | 45 | (C) Current Tax Assets (Net) | 15 | 13 |
| (D) Liabilities for current tax (Net) | 171 | 154 | (D) Other Current Assets | 772 | 639 |
| Total Current Liabilities | 9,611 | 8,523 | Total Current Assets | 11,293 | 9,388 |
| GRAND TOTAL - EQUITIES & LIABILITES | 13,822 | 11,653 | GRAND TOTAL – ASSETS | 13,822 | 11,653 |
| | | | | | 16 |

FINANCIALS - CONSOLIDATED




Market Data (Bloomberg – ION IN, Reuters – IONX.BO)





SHAREHOLDING PATTERN (AS ON 31st MARCH, 2020)



Disclaimer

Ion Exchange (India) Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited ("Company" or "IONEX"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: ion@valoremadvisors.com

THANK YOU